Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15


A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33 positive AML.

Fathi AT, Erba HP, Lancet JE, Stein EM, Ravandi F, Faderl S, Walter RB, Advani AS, DeAngelo DJ, Kovacsovics TJ, Jillella A, Bixby D, Levy MY, O'Meara MM, Ho PA, Voellinger J, Stein AS.

Blood. 2018 Jul 25. pii: blood-2018-03-841171. doi: 10.1182/blood-2018-03-841171. [Epub ahead of print]


A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia.

Stein EM, Walter RB, Erba HP, Fathi AT, Advani AS, Lancet JE, Ravandi F, Kovacsovics T, DeAngelo DJ, Bixby D, Faderl S, Jillella AP, Ho PA, O'Meara MM, Zhao B, Biddle-Snead C, Stein AS.

Blood. 2018 Jan 25;131(4):387-396. doi: 10.1182/blood-2017-06-789800. Epub 2017 Dec 1.


Immunization against HIF-1α Inhibits the Growth of Basal Mammary Tumors and Targets Mammary Stem Cells In Vivo.

Cecil DL, Slota M, O'Meara MM, Curtis BC, Gad E, Dang Y, Herendeen D, Rastetter L, Disis ML.

Clin Cancer Res. 2017 Jul 1;23(13):3396-3404. doi: 10.1158/1078-0432.CCR-16-1678. Epub 2016 Dec 30.


Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy.

Gopal AK, Bartlett NL, Forero-Torres A, Younes A, Chen R, Friedberg JW, Matous JV, Shustov AR, Smith SE, Zain J, O'Meara MM, Fanale MA.

Leuk Lymphoma. 2014 Oct;55(10):2328-34. doi: 10.3109/10428194.2013.876496. Epub 2014 Feb 24.


Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.

Younes A, Connors JM, Park SI, Fanale M, O'Meara MM, Hunder NN, Huebner D, Ansell SM.

Lancet Oncol. 2013 Dec;14(13):1348-56. doi: 10.1016/S1470-2045(13)70501-1. Epub 2013 Nov 15.


A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease.

Disis ML, Gad E, Herendeen DR, Lai VP, Park KH, Cecil DL, O'Meara MM, Treuting PM, Lubet RA.

Cancer Prev Res (Phila). 2013 Dec;6(12):1273-82. doi: 10.1158/1940-6207.CAPR-13-0182. Epub 2013 Oct 23.


Inner workings and regulatory inputs that control Polycomb repressive complex 2.

O'Meara MM, Simon JA.

Chromosoma. 2012 Jun;121(3):221-34. doi: 10.1007/s00412-012-0361-1. Epub 2012 Feb 19. Review.


Therapeutic cancer vaccines and translating vaccinomics science to the global health clinic: emerging applications toward proof of concept.

O'Meara MM, Disis ML.

OMICS. 2011 Sep;15(9):579-88. doi: 10.1089/omi.2010.0149. Epub 2011 Jul 6. Review.


Limiting the daily total nucleated cell dose of cryopreserved peripheral blood stem cell products for autologous transplantation improves infusion-related safety with no adverse impact on hematopoietic engraftment.

Khera N, Jinneman J, Storer BE, Heimfeld S, O'Meara MM, Chauncey TR, Lee SJ, Linenberger M.

Biol Blood Marrow Transplant. 2012 Feb;18(2):220-8. doi: 10.1016/j.bbmt.2011.06.003. Epub 2011 Jun 15.


A left/right asymmetric neuronal differentiation program is controlled by the Caenorhabditis elegans lsy-27 zinc-finger transcription factor.

Zhang F, O'Meara MM, Hobert O.

Genetics. 2011 Jul;188(3):753-9. doi: 10.1534/genetics.111.129064. Epub 2011 May 9.


Maintenance of neuronal laterality in Caenorhabditis elegans through MYST histone acetyltransferase complex components LSY-12, LSY-13 and LIN-49.

O'Meara MM, Zhang F, Hobert O.

Genetics. 2010 Dec;186(4):1497-502. doi: 10.1534/genetics.110.123661. Epub 2010 Oct 5.


Cis-regulatory mutations in the Caenorhabditis elegans homeobox gene locus cog-1 affect neuronal development.

O'Meara MM, Bigelow H, Flibotte S, Etchberger JF, Moerman DG, Hobert O.

Genetics. 2009 Apr;181(4):1679-86. doi: 10.1534/genetics.108.097832. Epub 2009 Feb 2.


Caenorhabditis elegans mutant allele identification by whole-genome sequencing.

Sarin S, Prabhu S, O'Meara MM, Pe'er I, Hobert O.

Nat Methods. 2008 Oct;5(10):865-7. doi: 10.1038/nmeth.1249. Epub 2008 Aug 1.


Genetic screens for Caenorhabditis elegans mutants defective in left/right asymmetric neuronal fate specification.

Sarin S, O'Meara MM, Flowers EB, Antonio C, Poole RJ, Didiano D, Johnston RJ Jr, Chang S, Narula S, Hobert O.

Genetics. 2007 Aug;176(4):2109-30.


Aberrant methylation of the maspin promoter is an early event in human breast cancer.

Futscher BW, O'Meara MM, Kim CJ, Rennels MA, Lu D, Gruman LM, Seftor RE, Hendrix MJ, Domann FE.

Neoplasia. 2004 Jul-Aug;6(4):380-9.

Supplemental Content

Loading ...
Support Center